Literature DB >> 8665502

Hypermethylation of the p16 gene in nasopharyngeal carcinoma.

K W Lo1, S T Cheung, S F Leung, A van Hasselt, Y S Tsang, K F Mak, Y F Chung, J K Woo, J C Lee, D P Huang.   

Abstract

We have recently reported that inactivation of the p16 gene by mutation and deletion is common in nasopharyngeal carcinoma (NPC). The present study demonstrates that hypermethylation of the 5' CpG island can serve as an alternative mechanism for inactivation of the p16 gene in this tumor. Using Southern blotting analysis and multiplex PCR, aberrant methylation of the 5' CpG island of the p16 gene was found in a NPC xenograft (xeno-666) and 6 (22%) of 27 primary tumors, but not in normal tissues of the nasopharynx. In the NPC xenograft (xeno-666) and its newly derived cell line (cell-666), both showing hypermethylation of the p16 gene, no p16 gene expression was found. After treatment with 5-aza-2'-deoxycytidine, reexpression of the p16 gene was detected in the cell line cell-666. These findings suggest that aberrant methylation of the 5' CpG island may participate in the transcriptional inactivation of the p16 gene in NPC. The present results further support that the p16 gene is the critical target on chromosome 9p21 for inactivation during the development of this disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665502

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases.

Authors:  Chi-Neu Tsai; Chia-Lung Tsai; Ka-Po Tse; Hwan-You Chang; Yu-Sun Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-10       Impact factor: 11.205

2.  Methylation status of p16 gene in colorectal carcinoma and normal colonic mucosa.

Authors:  Jing Zhang; Mao-De Lai; Jian Chen
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

3.  Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells.

Authors:  Richeng Jiang; Giulia Cabras; Wang Sheng; Yixin Zeng; Tadamasa Ooka
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

4.  p16 promoter hypermethylation is associated with increased risk of nasopharyngeal carcinoma.

Authors:  Yang Shao; Hongguo Jiang; Xiaoming Wu; Ying Luo; Wenru Tang
Journal:  Mol Clin Oncol       Date:  2014-08-20

5.  Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation.

Authors:  J Y Fang; J A Mikovits; R Bagni; C L Petrow-Sadowski; F W Ruscetti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis.

Authors:  Liangru Ke; Hufeng Zhou; Chong Wang; Geng Xiong; Yanqun Xiang; Yihong Ling; Abdelmajid Khabir; George S Tsao; Yixin Zeng; Musheng Zeng; Pierre Busson; Elliott Kieff; Xiang Guo; Bo Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-22       Impact factor: 11.205

7.  Aberrant promoter methylation of p16 in colorectal adenocarcinoma in North Indian patients.

Authors:  Pooja Malhotra; Rakesh Kochhar; Kim Vaiphei; Jai Dev Wig; Safrun Mahmood
Journal:  World J Gastrointest Oncol       Date:  2010-07-15

Review 8.  Nasopharyngeal carcinoma: an evolving paradigm.

Authors:  Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-30       Impact factor: 66.675

Review 9.  Locally advanced nasopharyngeal cancer.

Authors:  J F Ensley; E Youssef; H Kim; G Yoo
Journal:  Curr Treat Options Oncol       Date:  2001-02

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.